Global Parkinson s Disease Therapeutics Market Size By Type (Oral, Transdermal), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Parkinson’s Disease Therapeutics Market was valued at USD 5.6 billion in 2023 and is projected to reach USD 10.3 billion by 2031, growing at a CAGR of 7.9% during the forecast period (2023–2031). The market's growth is primarily driven by the rising prevalence of Parkinson’s disease, an aging global population, and advancements in therapeutic solutions. Increased R&D investment in neurodegenerative disease management and supportive government initiatives are further bolstering the market. Enhanced diagnostic capabilities and improved access to healthcare are also contributing to the growing demand for effective Parkinson’s disease therapeutics globally.

Drivers:

1. Increasing Prevalence of Parkinson’s Disease:

The global incidence of Parkinson’s disease is rising, particularly among the elderly. As life expectancy increases, so does the number of people susceptible to age-related neurological disorders, driving demand for effective treatments.

2. Advancements in Drug Development and Delivery:

Ongoing innovation in Parkinson’s therapeutics, including extended-release formulations, gene therapy, and neuroprotective drugs, is enhancing treatment efficacy and improving patient outcomes.

3. Government Support and Healthcare Access:

Government initiatives aimed at increasing awareness, funding for research, and improving access to neurologic care are positively influencing market growth. Additionally, the expansion of healthcare infrastructure in emerging economies is contributing to increased diagnosis and treatment.

Restraints:

1. High Cost of Treatment:

The cost of long-term Parkinson’s disease management can be prohibitive, especially with the inclusion of advanced therapies, supportive care, and hospitalization, limiting accessibility for patients in low- and middle-income countries.

2. Limited Availability of Disease-Modifying Therapies:

While symptomatic treatments exist, there is still a lack of curative or disease-modifying therapies for Parkinson’s, representing a significant medical gap that hinders optimal patient outcomes.

Opportunity:

1. Emerging Gene and Cell-Based Therapies:

The emergence of gene therapy and stem cell-based interventions presents exciting opportunities for modifying the progression of Parkinson’s disease. These innovations are expected to attract significant investments and reshape treatment paradigms.

2. Market Expansion in Developing Regions:

Rising awareness and improved healthcare systems in developing countries such as India, Brazil, and China offer vast untapped potential. As diagnostic and treatment accessibility improves, so will the demand for Parkinson’s therapeutics.

Market by System Type Insights:

Based on system type, the Levodopa and Carbidopa segment accounted for the largest market share in 2023. As the gold standard for treating Parkinson’s symptoms, these medications remain widely used for their effectiveness in reducing motor symptoms. However, dopamine agonists and MAO-B inhibitors are gaining traction due to fewer long-term side effects and better tolerability in younger patients.

Market by End-use Insights:

Hospitals led the market in 2023, accounting for the largest revenue share. Due to the need for neurologist supervision and access to complex diagnostic and therapeutic equipment, hospitals continue to dominate. However, homecare settings are expected to grow rapidly owing to the increasing use of telemedicine and wearable technologies that enable remote monitoring of patients.

Market by Regional Insights:

North America dominated the market in 2023 due to its high awareness, strong healthcare infrastructure, and active clinical research landscape. The U.S. alone accounted for a substantial share owing to advanced diagnostics and a high number of patients. Asia-Pacific is expected to experience the highest growth rate during the forecast period, driven by increasing elderly populations and greater access to neurological care in countries like China, India, and Japan.

Competitive Scenario:

Key players in the global Parkinson’s disease therapeutics market include AbbVie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Merck & Co., Amneal Pharmaceuticals, Lundbeck A/S, Sun Pharma, UCB S.A., and Acorda Therapeutics. These companies are focused on innovation, expanding their therapeutic pipelines, and entering strategic collaborations.

Key Developments:

In 2023, AbbVie Inc. initiated a Phase III clinical trial for a next-gen formulation of carbidopa/levodopa with enhanced bioavailability.

In 2024, Lundbeck A/S partnered with a biotechnology firm to develop a gene therapy candidate targeting early-stage Parkinson’s.

Novartis AG received Fast Track designation from the FDA in 2022 for its new MAO-B inhibitor therapy for Parkinson’s disease.

Scope of Work – Global Parkinson’s Disease Therapeutics Market

Report Metric Details

Market Size (2023) USD 5.6 billion

Projected Market Size (2031) USD 10.3 billion

CAGR (2023–2031) 7.9%

Key Segments By System Type (Levodopa/Carbidopa, Dopamine Agonists, MAO-B Inhibitors), By End-use (Hospitals, Clinics, Homecare Settings)

Growth Drivers Aging population, drug innovation, and increasing diagnosis rates

Opportunities Gene therapy, market penetration in emerging regions

FAQs:

1) What is the current market size of the Global Parkinson’s Disease Therapeutics Market?

The market was valued at USD 5.6 billion in 2023.

2) What is the major growth driver of the Global Parkinson’s Disease Therapeutics Market?

The major growth driver is the increasing prevalence of Parkinson’s disease globally, especially among aging populations.

3) Which is the largest region during the forecast period in the Global Parkinson’s Disease Therapeutics Market?

North America is expected to remain the largest region during the forecast period.

4) Which segment accounted for the largest market share in the Global Parkinson’s Disease Therapeutics Market?

The Levodopa and Carbidopa segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Parkinson’s Disease Therapeutics Market?

Key players include AbbVie Inc., Novartis AG, Teva Pharmaceuticals, GlaxoSmithKline, and Lundbeck A/S.